Alexander Kiani
Erlangen, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 57 publications
Efficacy of imatinib maintenance after stem cell transplantation for Ph+/BCR::ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease.
Journal: Leukemia & lymphoma
Published: August 02, 2026
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 18, 2025
Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.
Journal: Leukemia
Published: October 30, 2025
Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629).
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 28, 2025
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 13, 2025
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.
Journal: American journal of hematology
Published: June 25, 2025
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.
Journal: Leukemia
Published: June 10, 2025
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 05, 2025
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 13, 2025
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 07, 2025
Quality-assured treatment in certified cancer center networks in upper Franconia, Germany: a population-centered retrospective cohort analysis based on data of the Bavarian cancer registry.
Journal: BMC health services research
Published: August 05, 2024
Last Updated: 09/26/2026